Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances

Overview

Journal Thyroid

Date 2009 Dec 17

PMID 20001721

Citations 21

Authors

Martin Schlumberger

Steven I Sherman

Affiliations

Soon will be listed here.

Abstract

Treatment of metastatic differentiated thyroid cancer is first based on the use of radioiodine and thyrotropin-suppressive thyroid hormone treatment. The recent availability of molecular-targeted therapies has lead to reconsideration of the treatment strategy in differentiated thyroid cancer patients with distant metastases who are resistant to radioiodine therapy. In those with progressive disease, treatment with kinase inhibitors should be offered preferably in the context of a prospective trial.

Citing Articles

Vernodalin Triggers ROS-Mediated Apoptosis in TPC-1 Human PapillaryThyroid Cancer Cells Suppression of the MAPKs Signaling Pathway.

Yang X, Wei M, An Y, Liang Q, Nan J, Vijayalakshmi A Comb Chem High Throughput Screen. 2024; 27(14):2151-2158.

PMID: 39099452 DOI: 10.2174/0113862073286226240220092357.

Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network.

Bonichon F, De Baere T, Berdelou A, Leboulleux S, Giraudet A, Cuinet M Endocrine. 2021; 72(3):798-808.

PMID: 33770383 DOI: 10.1007/s12020-020-02580-2.

Role of laser ablation in multimodal treatment of radioiodine- refractory bone metastases of thyroid cancer: a retrospective study.

Pacella C, Di Stasio E, Guglielmi R, Baroli A, Pedrazzini L, Misischi I Endocrine. 2020; 70(2):338-347.

PMID: 32378155 DOI: 10.1007/s12020-020-02314-4.

Downregulation of miR-381 is associated with poor prognosis in papillary thyroid carcinoma.

Huang T, Yi D, Xu L, Bu E, Zhu C, Sang J Int J Clin Exp Pathol. 2020; 10(12):11610-11616.

PMID: 31966518 PMC: 6966045.

Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.

Fleeman N, Houten R, Bagust A, Richardson M, Beale S, Boland A Health Technol Assess. 2020; 24(2):1-180.

PMID: 31931920 PMC: 6983913. DOI: 10.3310/hta24020.